A Single Site, Randomized, Double-blind, Placebo-controlled Phase Ib Study, to Evaluate the Chemoprotective Activity of a Single Dose of MMV390048 in a Controlled P. Falciparum Sporozoite Infection Model in Non-immune Healthy Volunteers
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2018
At a glance
- Drugs MMV 390048 (Primary)
- Indications Falciparum malaria
- Focus First in man; Pharmacodynamics
- 01 Feb 2018 Status changed from suspended to withdrawn prior to enrolment.
- 13 Dec 2017 Status changed from not yet recruiting to suspended.
- 27 Jun 2017 New trial record